GAMMA Investing LLC Raises Holdings in Revvity, Inc. (NYSE:RVTY)

GAMMA Investing LLC lifted its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 15,023.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 287,035 shares of the company's stock after acquiring an additional 285,137 shares during the period. GAMMA Investing LLC owned approximately 0.24% of Revvity worth $30,368,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its stake in shares of Revvity by 16.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after acquiring an additional 2,969,326 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Revvity by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company's stock worth $1,594,930,000 after acquiring an additional 156,679 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Revvity by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock worth $851,764,000 after acquiring an additional 1,151,821 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Revvity by 0.4% during the fourth quarter. Janus Henderson Group PLC now owns 6,358,952 shares of the company's stock worth $709,725,000 after purchasing an additional 23,650 shares during the period. Finally, EdgePoint Investment Group Inc. lifted its holdings in shares of Revvity by 51.1% during the fourth quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock worth $452,939,000 after purchasing an additional 1,372,456 shares during the period. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Stock Performance

NYSE:RVTY traded down $1.97 during trading hours on Thursday, reaching $90.43. The company had a trading volume of 777,069 shares, compared to its average volume of 955,183. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The firm has a market cap of $10.66 billion, a PE ratio of 40.92, a price-to-earnings-growth ratio of 3.82 and a beta of 0.97. The business's 50 day moving average price is $94.06 and its 200-day moving average price is $107.74. Revvity, Inc. has a 1-year low of $87.70 and a 1-year high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.05. The business had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The business's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 EPS. Research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Friday, July 18th. Revvity's payout ratio is 11.91%.

Analyst Ratings Changes

A number of research firms recently commented on RVTY. The Goldman Sachs Group decreased their target price on Revvity from $140.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Barclays decreased their target price on Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. JPMorgan Chase & Co. decreased their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a report on Tuesday, April 29th. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, UBS Group raised Revvity from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.